News & Updates
Filter by Specialty:
Subgroup analyses boost masupirdine potential for AD
15 Aug 2022
byAudrey Abella
Post hoc data from a phase II study presented at AAIC 2022 continue to demonstrate the potential of masupirdine (SUVN-502), a selective 5-HT6 receptor antagonist, as a treatment alternative for the management of neuropsychiatric and cognitive symptoms of Alzheimer’s disease (AD).
Subgroup analyses boost masupirdine potential for AD
15 Aug 2022
Depression, anxiety, sleep troubles common in primary Sjögren’s syndrome
13 Aug 2022
Patients with primary Sjögren’s syndrome (pSS) show high levels of depression, anxiety, and sleep disturbances, reports a recent study. Cognitive impairments are also prevalent in this patient population.
